AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05191082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal Wound
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
Study NCT05191082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palatal Wound treated with Silk Fibroin Film
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
Study NCT05191082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palatal Wound treated with Neurotensin-loaded Silk Fibroin Film
Description: With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with neurotensin and 4.0 silk sutures.
Study NCT01408238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Four different concentrations of Secale cereale allergen extract, positive control and negative control
Description: 4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
Study NCT02857712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
Study NCT04732377 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erector spinae block with bupivacaine
Description: Group (A) (control group):~Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.
Study NCT04732377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block with bupivacaine and dexmedetomidine
Description: Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
Study NCT00834548 — intervention group
Intervention type: PROCEDURE
Intervention: Whole body magnetic resonance angiography (WB-MRA)
Description: WB-MRA will be performed once in each patient.
Study NCT02329925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Stabilizing Device (TSD)
Description: Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
Study NCT05316363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT
Description: Suboccipital Release - Finger pads are placed onto suboccipital musculature and a smooth, gentle, and rhythmic laterocephalad traction is applied to reduce muscle tension.~Paraspinal Inhibition - Hands are placed under the patient's thoracolumbar spine and contract the erector spinae tissue to draw the thoracolumbar spine into extension and hold until relaxation is felt.~Rib Raising - Hands are placed under the subject's thorax and contact the rib angles with finger pads. Fingers are flexed while adding an anteriolateral traction directed at the rib angle while maintaining neutral wrists. Arms are used as a lever by leaning forward thus creating a fulcrum with the treatment table with a smooth, rhythmic motion. This motion is repeated several times throughout the entire thoracic region, unilaterally and then switch sides.~Diaphragm Release - Hands apply a gentle pressure until a barrier or point of ease of the fascia is felt and hold that position until tissue response is felt.
Study NCT02638012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floseal
Description: Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
Study NCT02638012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packing
Description: If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
Study NCT00506389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.
Study NCT00506389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
Study NCT03697239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 25, 37.5, 56.25 or 75 grams/m2
Study NCT03697239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein-bound
Description: 125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
Study NCT03697239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 in 500\*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
Study NCT03697239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 in 500\*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
Study NCT05059197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP collagen peptide
Description: Health functional food
Study NCT05059197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00003323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: finasteride
Description: 5 mg/d PO
Study NCT00003323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: 250 mg PO tid
Study NCT00003323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Assessment survey administered at baseline, and 3 \& 6 months post initiation of treatment
Study NCT04600999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]
Study NCT00188539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-treatment tumour oxygen measurements (under anesthesia)
Study NCT03774680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab nanoparticles
Description: The active group will receive cetuximab in nanoparticles as an anti-microbial drug.
Study NCT03774680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral approved anticancer drug
Description: The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
Study NCT01067963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer assisted education and motivational interviewing.
Description: 9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
Study NCT01067963 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group talks/social chat
Description: 9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
Study NCT03757845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: subjects will be asked to eat from a sub-menu items compliant with Mediterranean Diet
Study NCT03162315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freeze all
Study NCT00844922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900636
Description: Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression.
Study NCT00844922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02566850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso
Description: powered lower extremity exoskeleton
Study NCT04452786 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic sleeve gastroplasty
Description: Four-hour solid mixed meal test
Study NCT04452786 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic sleeve gastrectomy
Description: Four-hour solid mixed meal test
Study NCT02815566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir-alafenamide-emtricitabine
Description: comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
Study NCT02815566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir-emtricitabine
Description: comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
Study NCT03249454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
Study NCT01013753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
Study NCT01013753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) high
Description: Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study NCT01013753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) medium
Description: Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study NCT02347358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JRecanTM blood FR device
Description: JRecanTM blood flow recanalisation device
Study NCT02347358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV r-tPA
Description: intravenous recombinant human tissue plasminogen activator
Study NCT01013753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) very low
Description: Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study NCT01013753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 mcg
Description: Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
Study NCT04430348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-35
Description: Monoclonal antibody PTX-35
Study NCT01013753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI 1744) low
Description: Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study NCT00906581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Problem-Solving Treatment
Description: 6 sessions of problem-solving treatment delivered via computer
Study NCT04630314 — intervention group
Intervention type: DEVICE
Intervention: Percutaneus Coronary Intervention
Description: Covered Stent
Study NCT02373930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
Study NCT01764581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tacrolimus regulation according to ImmuKnow values
Description: Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
Study NCT00344825 — intervention group
Intervention type: DRUG
Intervention: Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)
Description: Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance.
Study NCT04079725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined trabeculotomy-trabeculectomy with mitomycin c
Description: Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease
Study NCT02164188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flourishing protocol
Description: This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
Study NCT00599313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg/day orally each of Days 1-28 of each 6 week cycle
Study NCT04338997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZD174
Description: Small molecule inhibitor of NLRP3
Study NCT03403517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery
Study NCT03403517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
Study NCT04370899 — intervention group
Intervention type: OTHER
Intervention: lifestyle assessment
Description: A semi-quantitative assessment of the consumption of different food groups will be carried out using a frequency questionnaire validated by the Spanish population27. This questionnaire consists of 137 food items and will be obtained by the dietitian of our Unit (see annex).~The child population and/or their parents will be instructed on how to fill the data in the food diary for a period of 3 days, in order to be able to analyse the nutritional composition of the intake and the effect on the lipid profile. The first food register, will be obtained at the collection visit before starting any type of treatment. Another food diary will be included after one year.~Physical activity will be collected from the Minnesota Test and we will ask about the consumption of tobacco.
Study NCT02654509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104
Description: Eastern Equine Encephalitis Vaccine, Inactivated, Dried
Study NCT00258661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
Study NCT00258661 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Light-touch Treatment
Description: In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
Study NCT01635647 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP and MVA ME-TRAP
Description: ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 1 x 10\^8 pfu heterologous prime-boost immunisation
Study NCT01635647 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies vaccine
Description: Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
Study NCT00126217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacille Calmette Guerin (BCG)
Description: 0,1 ml, revaccination at 19 months of age
Study NCT00992836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine
Description: Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
Study NCT01724190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study NCT01724190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04694638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body position change
Description: combined use of prone positioning and high-flow nasal cannula (HFNC) and non-invasive positive pressure ventilation (NIPPV) can reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to COVID-19 infection.
Study NCT02347865 — intervention group
Intervention type: DRUG
Intervention: AMG 162 - Prolia
Description: 500 patients
Study NCT02373930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
Study NCT02347865 — intervention group
Intervention type: DRUG
Intervention: AMG 162 - Prolia
Description: 250 patients, one year later
Study NCT03144206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
Study NCT03243890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).
Description: Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
Study NCT03243890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the patients are randomized to placebo treatment (no active treatment).
Study NCT01149252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psoralait
Description: Cream to be used as instructed.
Study NCT01149252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream.
Description: Cream to be used as instructed
Study NCT00442689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: 250 mg twice daily
Study NCT00442689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 mcg and drospirenone 3 mg
Description: one active pill per day for three weeks and then 1 sugar pill per day for one week
Study NCT00442689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01784185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual bronchoscopy guided transbronchial needle aspiration
Study NCT01784185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endobronchial ultrasound guided transbronchial needle aspiration
Description: endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
Study NCT01410604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
Study NCT01410604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet of 500 mg oral placebo every 12 hours for 3 months.
Study NCT02027571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Description: ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.